Analysis of efficacy and safety of ixekizumab in the treatment of severe psoriasis
Objective To explore the clinical efficacy of ixekizumab in the treatment of severe psoriasis,in order to provide reference for the development of relevant clinical treatment plans.Methods A total of 72 patients with severe psoriasis admitted to Tengzhou Central People's Hospital from October 2019 to May 2020 were selected as the study subjects and randomly divided into control group and study group,with 36 cases in each group.The control group received routine drug treatment,while the study group received subcutaneous injection treatment of ixekizumab.Both groups were treated for 6 months.The levels of inflammatory factors,the expression of CKLF1 in T lymphocytes,red blood cells and neutrophils,T lymphocyte subsets,PASI socres and the incidence of adverse reactions between two groups were compared.Results After 6 months of treatment,the levels of IL-17,IL-1 β,IL-6 and TNF-α in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05);the expression ratio of CKLF1 in T lymphocytes,red blood cells and neutrophils in the study group were higher than those in the control group,and the differences were statistically significant(P＜0.05);the proportion of CD3+,CD4+and CD8+positive cells in both groups increased compared to before treatment,while CD4+/CD8+decreased compared to before treatment,moreover,the proportion of CD3+positive cell in the study group was higher than that in the control group,and the differences were statistically significant(P＜0.05).The PASI scores of the study group at 1,3 and 6 months of treatment were lower than those of the control group,and the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the control group and the study group were 22.22％and 16.67％,respectively,and the difference was not statistically significant(x2=0.355,P＞0.05).Conclusion Ixekizumab had a significant therapeutic effect in the treatment of severe psoriasis,which could effectively improve the body's immunity and CKLF1 expression,reduce the levels of inflammatory factors and chemokines,and had good safety and tolerance.
NETL
NSTL
万方数据
